Spyre Therapeutics Reports Positive Phase 2 SPY003 Data In Ulcerative Colitis

Spyre Therapeutics reported positive Phase 2 SPY003 data in ulcerative colitis, with a statistically significant 10-point reduction in RHI at Week 12 (p<0.0001), plus 20% clinical remission and 30% endoscopic improvement.